Compositions and methods for the enhancement of soluble amyloid beta oligomer (ADDL) uptake and clearance
US7964359B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | May 11, 2007 |
| Grant date | Jun 21, 2011 |
| Priority date | — |
| Expiry date | Aug 27, 2028 |
Classification
- Technology area (CPC G)Physics
- CPC primaryG01N2500/00
- WIPO fieldMeasurement
- WIPO sectorInstruments
Abstract
The present invention relates to methods for enhancing the cellular uptake and clearance of soluble oligomeric Aβ peptide assemblies from the environment surrounding both neuronal and non-neuronal cells. Oligomeric Aβ peptide assembly uptake and clearance is achieved via an agent that enhances insulin receptor signaling. Such ADDL uptake enhancers represent effective anti-ADDL therapeutics for use in the therapeutic treatment and/or prophylactic treatment of diseases including Alzheimer's disease, Down's syndrome, and the like, in which compromised nerve cell function is linked to the formation and/or the activity of soluble oligomeric Aβ peptide assemblies, also known as ADDLs, and ADDL-related assemblies.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.